lifestyle.californiaconsumerbanking.com

Author: Edgewise Therapeutics

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

February 2, 2026
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

January 13, 2026
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

January 6, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

January 5, 2026
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

December 24, 2025
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

November 26, 2025